ProAmpac’s Recycle Ready Retort Pouch Validated by Two Advanced Recycling Firms
ProAmpac, a leader in flexible packaging and material science, announced that two independent advanced recycling firms confirmed their ProActive Recycle Ready Retort RT-3000 pouches met the criteria for chemical recycling. By processing materials that cannot be mechanically recycled due to composition or product residue, advanced recycling produces a quality polymer that can be re-introduced into the supply chain.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005962/en/
ProAmpac's RT-3000 Recycle Ready Retort Structure (Photo: Business Wire)
“Advanced recycling will be a critical part of the world’s future recycling infrastructure as brands transition to packaging that supports the circular economy. ProAmpac has tested our RT-3000 offering in two separate advanced recycling processes to ensure that the mono-material structure is truly a circular solution,” states Adam Grose, chief commercial officer.
Generally, mono-material structures are more economically viable than mixed material structures in advanced recycling systems because they allow for higher recovery and less unrecoverable waste. In both tests, the RT-3000 retort pouches met the yield requirements as well as the quality parameters for further recycling.
“RT-3000 passed two separate depolymerization processes with very high yields. With the purification process of the recycled monomers (r-monomers), the r-monomers showed excellent quality for the re-polymerization steps. This chemical recycling validation ratifies ProAmpac’s commitment to our customers seeking recyclable solutions across all product applications,” states Hesam Tabatabaei, vice president of product development and innovation.
To learn more about ProActive Recycle Ready Retort RT-3000 or other ProActive Sustainability® solutions contact Marketing@ProAmpac.com or go to ProAmpac.com.
About ProAmpac
ProAmpac is a leading global flexible packaging company with a comprehensive product offering, providing creative packaging solutions, industry-leading customer service and award-winning innovation to a diverse global marketplace. ProAmpac’s approach to sustainability – ProActive Sustainability® – provides innovative sustainable flexible packaging products to help our customers achieve their sustainability goals. We are guided in our work by four core values that are the basis for our success: Integrity, Intensity, Innovation, and Involvement. Cincinnati-based ProAmpac is owned by Pritzker Private Capital along with management and co-investors. For more information, visit ProAmpac.com or contact Media@ProAmpac.com.
About Pritzker Private Capital
Pritzker Private Capital partners with middle-market companies based in North America with leading positions in the manufactured products, services and healthcare sectors. The firm's differentiated, long duration capital base allows for efficient decision-making, broad flexibility with transaction structure and investment horizon, and alignment with all stakeholders. Pritzker Private Capital builds businesses for the long term and is an ideal partner for entrepreneur- and family-owned companies. Pritzker Private Capital is a signatory to the United Nations Principles for Responsible Investment (PRI). For more information, visit PPCPartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005962/en/
Contact information
Kristy Paulin
ProAmpac
(413) 875-9872
Kristy.Paulin@ProAmpac.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FIM Partners and Loomis Sayles Announce Transition of Global Emerging Market Equities Team6.11.2025 15:00:00 EET | Press release
FIM Partners today announced it has entered into an agreement with Loomis, Sayles & Company, to acquire the Global Emerging Market Equities (GEM) investment team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106799715/en/ Overview of the GEM Team and FIM Led by Ashish Chugh, Portfolio Manager and Head of Global Emerging Market Equities, the GEM Team follows a high conviction investment philosophy anchored in deep, fundamental research and a private equity-style approach to diligence and ownership. The team invests in high quality companies and those transitioning toward higher quality, leveraging its proprietary insights to identify long-term value creation opportunities across emerging markets. With an active, bottom-up, benchmark-agnostic strategy, the team builds high-conviction, concentrated, quality-focused portfolios that reflect a true ownership mindset. Founded in 2008, FIM Partners is a leading asset manager fo
Debiopharm Takes a Step Forward for Children With CPP: Enrollment Completion for the Phase III Trial Evaluating the First Ever Yearly Injectable Triptorelin Formulation6.11.2025 15:00:00 EET | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to develop innovative therapies and to improve patient quality of life, today announced the successful completion of patient enrollment in its open-label, single-arm, multi-center Phase III study (NCT06129539) ‘A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULATM)’. The completion of enrollment is a significant milestone for the development of Debio 4326, a unique injectable, biodegradable 12-month extended-release formulation of the established treatment, triptorelin. The LIBELULATM trial is being conducted across the United States, Argentina, Brazil, Chile, and Mexico, leveraging Debiopharm's proprietary DEBIO SPHERETMLong-Acting Release Platform technology and expertise in developing extended-release formulations to potentially reduce the freq
IFCO’s circular model delivers global impact: Five years of progress marked with 2025 ESG report6.11.2025 15:00:00 EET | Press release
IFCO, a global leader in reusable packaging containers (RPCs) for fresh food, today published its ESG Report 2025, marking the successful completion of its five-year sustainability strategy, Thriving in the Circular Economy. Over the last five years, IFCO has advanced every one of its 18 ESG goals, delivering measurable progress for the planet, people, partners, and customers while laying the groundwork for the next iteration of its sustainability objectives. The ESG Report 2025 confirms IFCO’s position as a global leader in circular packaging and highlights the role of reuse in addressing some of the sector’s most pressing challenges. Since IFCO’s founding in 1992, it has dedicated itself to eliminating packaging and food waste in the fresh grocery supply chain, enhancing efficiencies across the value chain and sharing the resulting long-term value with stakeholders. With operations in more than 50 countries and partnerships with 18,000 growers and 300 retailers, IFCO’s scale enables
U.K. Continues to Lead Europe in Shareholder Activism with 44% Year-on-Year Surge, According to Diligent Market Intelligence6.11.2025 14:00:00 EET | Press release
The U.K. remains Europe’s most active market for shareholder activism, with a 44% year-on-year increase in targeted companies, according to the Corporate Governance in Europe 2025report by Diligent Market Intelligence (DMI). Between September 2024 and August 2025, 52 U.K. companies faced activism, compared to 36 over the same timeframe in 2024, underscoring the market’s heightened shareholder engagement. “The U.K. remains the primary driver of public-facing engagement in Europe, with other European markets increasingly witnessing similar strategies when behind-the-scenes efforts fail,” said Josh Black, Editor-in-Chief, Diligent Market Intelligence. “Activism in Europe runs the full gamut from hostile media campaigns to more private engagements but there is no doubt that boards should prepare for anything in what looks likely to be a very busy annual meeting season.” Produced in association with White & Case, a global law firm, thereport reveals that while smaller-cap companies accounte
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates6.11.2025 13:00:00 EET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2025. “These strong financial results reinforce our position as a global oncology leader with exceptional topline growth and a strong balance sheet,” said John V. Oyler, Co-Founder, Chairman and CEO at BeOne. “BRUKINSA is now the global revenue leader in the BTKi class, supported by long-term efficacy and safety data and a growing body of evidence reinforcing its scientific hypothesis of sustained BTK inhibition. Our late-stage hematology portfolio continues to advance with sonrotoclax, a potentially best-in-class BCL2 inhibitor that has demonstrated impressive clinical results, and our BTK CDAC BGB-16673, further strengthening our leadership in B cell malignancies, including CLL. With one of the most promising oncology pipelines in the industry, we are poised to deliver multiple data and regulatory milestones that wi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom